Detailed information for compound 172611

Basic information

Technical information
  • TDR Targets ID: 172611
  • Name: 2-methyl-1-(2-morpholin-4-ylethyl)indole-3-ca rbaldehyde
  • MW: 272.342 | Formula: C16H20N2O2
  • H donors: 0 H acceptors: 1 LogP: 1.46 Rotable bonds: 4
    Rule of 5 violations (Lipinski): 1
  • SMILES: O=Cc1c(C)n(c2c1cccc2)CCN1CCOCC1
  • InChi: 1S/C16H20N2O2/c1-13-15(12-19)14-4-2-3-5-16(14)18(13)7-6-17-8-10-20-11-9-17/h2-5,12H,6-11H2,1H3
  • InChiKey: VLPKXRQLMVWESP-UHFFFAOYSA-N  

Network

Hover on a compound node to display the structore

Synonyms

  • 2-methyl-1-(2-morpholinoethyl)indole-3-carbaldehyde
  • 2-methyl-1-(2-morpholinoethyl)-3-indolecarboxaldehyde

Targets

Known targets for this compound

No curated genes were found associated with this compound

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Echinococcus multilocularis mitogen activated protein kinase 0.2183 0.5 0.5
Trypanosoma cruzi mitogen-activated protein kinase 11, putative 0.2183 0.5 0.5
Leishmania major mitogen activated protein kinase, putative,map kinase, putative 0.2183 0.5 0.5
Trichomonas vaginalis CMGC family protein kinase 0.2183 0.5 0.5
Loa Loa (eye worm) CMGC/MAPK/ERK1 protein kinase 0.2183 0.5 0.5
Trichomonas vaginalis CMGC family protein kinase 0.2183 0.5 0.5
Trypanosoma cruzi mitogen-activated protein kinase 11, putative 0.2183 0.5 0.5
Toxoplasma gondii CMGC kinase, MAPK family (ERK) MAPK-1 0.2183 0.5 0.5
Schistosoma mansoni serine/threonine protein kinase 0.2183 0.5 0.5
Trypanosoma brucei protein kinase, putative 0.2183 0.5 0.5
Trichomonas vaginalis CMGC family protein kinase 0.2183 0.5 0.5
Echinococcus granulosus mitogen activated protein kinase 3 0.2183 0.5 0.5
Giardia lamblia Kinase, CMGC MAPK 0.2183 0.5 0.5
Trypanosoma brucei mitogen activated protein kinase 4, putative 0.2183 0.5 0.5
Trichomonas vaginalis CMGC family protein kinase 0.2183 0.5 0.5
Trypanosoma cruzi mitogen activated protein kinase 4, putative 0.2183 0.5 0.5
Echinococcus multilocularis mitogen activated protein kinase 3 0.2183 0.5 0.5
Leishmania major mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 0.2183 0.5 0.5
Trypanosoma cruzi mitogen activated protein kinase 2, putative 0.2183 0.5 0.5
Echinococcus granulosus mitogen activated protein kinase 0.2183 0.5 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (functional) = 656 nM Concentration required to inhibit electrically induced contractions in isolated mouse vas deferens preparation in vitro ChEMBL. 7636873
IC50 (functional) = 656 nM Concentration required to inhibit electrically induced contractions in isolated mouse vas deferens preparation in vitro ChEMBL. 7636873
Inhibition (binding) = 37 % Concentration of compound required to inhibit 50% of [3H]-WIN- 55212 binding to Cannabinoid receptor 1 in rat cerebellum membranes. ChEMBL. 7636873
Inhibition (binding) = 37 % Concentration of compound required to inhibit 50% of [3H]-WIN- 55212 binding to Cannabinoid receptor 1 in rat cerebellum membranes. ChEMBL. 7636873

Phenotypes

Whole-cell/tissue/organism interactions

Species name Source Reference Is orphan
Mus musculus ChEMBL23 7636873

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.